Analyst Ratings for Mirati Therapeutics (MRTX) [Buys]
MRTX Rating Summary
MRTX Price Target Summary
- Highest: $75.00 (Barclays)
- Lowest: $37.00 (Morgan Stanley)
- Average: $58.36
* Over Last 12-Mos
Overall Rating:
NEUTRAL
Rating Trend:
Avg. $ Target:
$58.36 (-0.6%)
* Over Last 12-Mos
Rating Score: 3.1 / 10
Percentile Rank: 27%
Avg. $ Target:
$58.36 (-0.6%)
* Over Last 12-Mos
Rating Score: 3.1 / 10
Percentile Rank: 27%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/25/2023 | Oppenheimer » Updated 8/9/2023 |
Jay Olson | Upgrade | Outperform (Perform) |
62.00 (56.00) |
43.84 (58.70) |
33.9% | Details |
| 5/20/2022 | Guggenheim | Michael Schmidt | Upgrade | Buy (Neutral) |
115.00 (N/A) |
59.61 (58.70) |
-1.53% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
